文献速递其他结缔组织病

间充质基质细胞通过修复cDC2细胞OXPHOS缺陷缓解系统性硬化症

Mesenchymal Stromal Cells Fuel Immunometabolic Reprogramming of Type 2 Conventional Dendritic Cells to Alleviate Systemic Sclerosis.
PubMed 文献 · Arthritis Rheumatol · 2026-10-05

本研究前瞻性评估间充质基质细胞(MSC)治疗系统性硬化症(SSc)的疗效与机制,整合蛋白组学、代谢组学及转录组学数据。MSC治疗6个月后显著改善皮肤纤维化并稳定肺功能,机制上修复致病性cDC2细胞的氧化磷酸化缺陷并抑制炎症通路。

要点

  • MSC治疗6个月显著降低mRSS(中位下降7.0)并稳定肺功能。
  • SSc中cDC2细胞存在内在OXPHOS缺陷,MSC治疗可修复该缺陷。
  • MSC治疗抑制hedgehog介导的纤维化通路及cDC2相关炎症通路。

核心结论

  • MSC通过靶向cDC2细胞上游OXPHOS缺陷实现免疫代谢重编程,恢复免疫稳态并缓解SSc。

研究设计与样本

  • 前瞻性评估MSC治疗SSc患者疗效,并整合配对多组学数据:蛋白组学(n=7)、代谢组学(n=7)、bulk RNA测序(n=6)和单细胞RNA测序(n=2)。
  • 基线疾病相关特征主要基于公开的外周血单个核细胞(PBMC)数据集定义(21例SSc vs 6例健康供者)。

主要发现

  • MSC治疗显著改善皮肤纤维化,中位改良Rodnan皮肤评分下降7.0(四分位距3.8-9.3),P<0.05,并稳定肺功能。
  • 血浆蛋白组学显示MSC治疗抑制hedgehog介导的纤维化通路(Padj<0.05)。
  • 转录组分析显示SSc中致病性cDC2细胞存在内在OXPHOS缺陷(Padj<0.05),MSC治疗修复该缺陷并抑制PBMC和血浆中cDC2相关炎症通路(Padj<0.05)。
  • 单细胞RNA测序显示cDC2细胞OXPHOS恢复且稳态亚群比例增加。

临床怎么用

  • MSC治疗可能作为改善SSc皮肤纤维化和稳定肺功能的潜在策略。
  • 靶向cDC2细胞OXPHOS缺陷或可成为SSc的免疫代谢治疗新方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to investigate the clinical efficacy and underlying mechanisms of mesenchymal stromal cell (MSC) therapy in systemic sclerosis (SSc). METHODS: We prospectively evaluated the efficacy of MSC therapy in patients with SSc. To elucidate the therapeutic mechanisms, we integrated paired multiomics data: proteomics (n = 7), metabolomics (n = 7), and both bulk (n = 6) and single-cell (n = 2) RNA sequencing. Baseline disease-associated signatures were mainly defined by publicly available data sets of peripheral blood mononuclear cells (PBMCs; 21 SSc vs 6 healthy donors). RESULTS: MSC therapy significantly ameliorated skin fibrosis (median modified Rodnan Skin Score decreased 7.0 [interquartile range 3.8-9.3]; P < 0.05) and stabilized lung function after six months. In parallel with these clinical improvements, plasma proteomic analysis demonstrated that MSC therapy suppressed hedgehog-mediated fibrotic pathways (adjusted P value [Padj] < 0.05). Transcriptomic profiling revealed that pathogenic type 2 conventional dendritic cells (cDC2s) exhibit intrinsic oxidative phosphorylation (OXPHOS) defects in SSc (Padj < 0.05). MSC therapy effectively repaired these defects and concurrently suppressed cDC2-related inflammatory pathways in PBMCs and plasma (Padj < 0.05). Consistent with these findings, single-cell RNA sequencing revealed OXPHOS recovery in cDC2s alongside an increased proportion of homeostatic subsets. CONCLUSION: Our study underscores the MSC-mediated immunometabolic reprogramming to restore immune homeostasis by targeting upstream OXPHOS defects of cDC2s in SSc.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Wang Z, Liu S, Liu X, et al. Mesenchymal Stromal Cells Fuel Immunometabolic Reprogramming of Type 2 Conventional Dendritic Cells to Alleviate Systemic Sclerosis. Arthritis Rheumatol. 2026. PMID: 42834011. doi:10.1002/art.70359

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。